Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the united states by the gonococcal isolate surveillance project, 2005 to 2013

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 998-1003

  Kirkcaldy, Robert D ^a   Soge, Olusegun ^b   Papp, John R ^a   Hook, Edward W ^c   Rio, Carlos Del ^d   Kubin, Grace ^e   Weinstock, Hillard S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Jefferson County Department of Health   (United States)

^d EMORY UNIVERSITY   (United States)

^e TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ADULT; AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; FEMALE; GONORRHEA; HUMAN; IC50; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; SENTINEL SURVEILLANCE; UNITED STATES; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; UNITED STATES; YOUNG ADULT;

EID: 84921919622     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04337-14     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. 2014. 2012 STD Surveillance Report. Centers for Disease Control and Prevention, Atlanta, GA.
2. Landman GA, Phillips LV, Friend L. 1958. Treatment of acute gonorrheal pelvic inflammatory disease: the use of benzathine penicillinGin the ambulatory patient. South Med J 51:899-902. http://dx.doi.org/10.1097 /00007611-195807000-00018.
3. Falk V. 1965. Treatment of acute non-tuberculous salpingitis with antibiotics alone and in combination with glucocorticoids: a prospective double blind controlled study of the clinical course and prognosis. Acta Obstet Gynecol Scand 44(Suppl 6):S3-S118.
4. Centers for Disease Control and Prevention. 2002. Increases in fluoro-quinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 51:1041-1044.
5. Jaffe HW, Biddle JW, Johnson SR, Wiesner PJ. 1981. Infections due to penicillinase-producing Neisseria gonorrhoeae in the United States: 1976-1980. J Infect Dis 144:191-197. http://dx.doi.org/10.1093/infdis/144 .2.191.
6. Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56:332-336.
7. Centers for Disease Control and Prevention. 2004. Increases in fluoro-quinolone-resistant Neisseria gonorrhoeae among men who have sex with men-United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 53:335-338.
8. Centers for Disease Control and Prevention. 2011. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR Morb Mortal Wkly Rep 60:873-877.
9. Centers for Disease Control and Prevention. 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61:590-594.
10. Barbee L, Kerani RP, Dombrowski JC, Soge OO, Golden MR. 2013. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhoea. Clin Infect Dis 56:1539-1545. http://dx.doi.org/10.1093/cid/cit084.
11. Centers for Disease Control and Prevention. 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend Rep 59(RR-12):1-110.
12. McLean CA, Wang SA, Hoff GL, Dennis LY, Trees DL, Knapp JS, Markowitz LE, Levine WC. 2004. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis 31:73-78. http://dx.doi.org/10.1097/01 .OLQ.0000109514.91508.FC.
13. Zarantonelli L, Borthagaray G, Lee E-H, Shafer WM. 1999. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother 43:2468-2472.
14. Johnson SR, Sandul AL, Parekh M, Wang SA, Knapp JS, Trees DL. 2003. Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. Int J Antimicrob Agents 21:414-419. http://dx.doi.org/10 .1016/S0924-8579(03)00039-6.
15. Soge OO, Harger D, Schafer S, Toevs K, Raisler KA, Venator K, Holmes KK, Kirkcaldy RD. 2012. Emergence of increased azithromycin resistance during unsuccessful treatment with Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 39:877-879. http: //dx.doi.org/10.1097/OLQ.0b013e3182685d2b.
16. Centers for Disease Control and Prevention. 2011. Neisseria gonorrhoeae with reduced susceptibility to azithromycin-San Diego County, California, 2009. MMWR Morb Mortal Wkly Rep 60:579-581.
17. Schwarcz SK, Zenilman JM, Schnell D, Knapp JS, Hook EW, III, Thompson S, Judson FN, Holmes KK. 1990. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. JAMA 264:1413-1417. http://dx.doi.org/10.1001/jama.1990.03450110059027.
18. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Centers for Disease Control and Prevention. 2014. Gonococcal Isolate Surveillance Project (GISP): protocol. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/std/gisp/GISP-Protocol-May -2014.pdf.
20. Hicks LA, Taylor TH, Hunter RJ. 2013. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med 368:1461-1462. http://dx.doi.org/10.1056 /NEJMc1212055.
21. Grijalva GC, Nuorti JP, Griffin MR. 2009. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 302:758-766. http://dx.doi.org/10.1001/jama.2009.1163.
22. McCaig LF, Besser RE, Hughes JM. 2003. Antimicrobial-drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 9:432-437. http://dx.doi.org/10.3201/eid0904.020268.
23. Young H, Moyes A, McMillan A. 1997. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 8:299-302. http://dx.doi.org/10.1258/0956462971920127.
24. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. 2011. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 16:pii=19833. http://www.eurosurveillance.org/View Article.aspx?ArticleId=19833.
25. Ng L-K, Martin I, Liu G, Bryden L. 2002. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 46:3020-3025. http://dx.doi.org/10.1128/AAC.46.9 .3020-3025.2002.
26. Chisholm SA, Dave J, Ison CA. 2010. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 54:3812-3816. http://dx .doi.org/10.1128/AAC.00309-10.
27. Hao H, Dai M, Wang Y, Peng D, Liu Z, Yuan Z. 2009. 23S rRNA mutation A2074C conferring high-level macrolide resistance and fitness cost in Campylobacter jenuni. Microb Drug Resist 15:239-243. http://dx .doi.org/10.1089/mdr.2009.0008.
28. Zeitouni S, Collin O, Andraud M, Ermel G, Kempf I. 2012. Fitness of macrolide resistant Campylobacter coli and Campylobacter jenuni. Microb Drug Resist 18:101-108. http://dx.doi.org/10.1089/mdr.2011.0188.
29. Maher MC, Alemayehu W, Lakew T, Gaynor BD, Haug S, Cevallos V, Keenan JD, Lietman TM, Porco TC. 2012. The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. PLoS One 7:e29407. http://dx.doi.org/10.1371/journal.pone.0029407.
30. Warner DM, Folster JP, Shafer WM, Jerse AE. 2007. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis 196:1804-1812. http://dx.doi.org/10 .1086/522964.
31. Galarza PG, Alcalá B, Salcedo C, Fernández L, Buscemi L, Pagano I, Oviedo C, Vázquez JA. 2009. Emergence of high level azithromycinresistant Neisseria gonorrhoeae strain located in the Argentina. Sex Transm Dis 36:787-788. http://dx.doi.org/10.1097/OLQ.0b013e3181b61bb1.
32. Palmer HM, Young H, Winter A, Dave J. 2008. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother 62:490-494. http://dx.doi.org/10.1093/jac/dkn235.
33. Katz AR, Komeya AY, Soge OO, Kiaha MI, Lee MVC, Wasserman GM, Maningas EV, Whelan AC, Kirkcaldy RD, Shapiro SJ, Bolan GA, Holmes KK. 2012. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 54:841-843. http://dx.doi.org/10.1093/cid/cir929.
34. Unemo M, Golparian D, Hellmark B. 2014. First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? Antimicrob Agents Chemother 58:624-625. http://dx.doi.org /10.1128/AAC.02093-13.
35. Allen VG, Seah C, Martin I, Melano RG. 2014. Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada. Antimicrob Agents Chemother 58: 2528-2534. http://dx.doi.org/10.1128/AAC.02608-13.
36. Dillon JA, Trecker MA, Thakur SD, Gonococcal Antimicrobial Surveillance Program Network in Latin America and Caribbean 1990-2011. 2013. Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities. Sex Transm Infect 89(Suppl 4):iv36-41. http://dx.doi.org/10.1136/sextrans -2012-050905.
37. Lahra MM, Lo YR, Whiley DM. 2013. Gonococcal antimicrobial resistance in the Western Pacific region. Sex Transm Infect 89(Suppl 4):iv19-23. http://dx.doi.org/10.1136/sextrans-2012-050906.
38. Health Protection Agency. 2008. GRASP: The Gonococcal Resistance to Antimicrobials Surveillance Programme: annual report. Health Protection Agency, London, United Kingdom. http://www.hpa.org.uk/webc /HPAwebFile/HPAweb-C/1221117895841.
39. Public Health England. 2012. GRASP 2012 report: The Gonococcal Resistance to Antimicrobials Surveillance Programme. Public Health England, London, United Kingdom. http://www.hpa.org.uk/webc/HPAweb File/HPAweb-C/1317140152190.
40. Kirkcaldy RD, Zaidi A, Hook EW, III, Holmes KK, Soge OO, del Rio C, Hall G, Papp JR, Bolan G, Weinstock HS. 2013. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 158:321-328. http://dx.doi.org/10 .7326/0003-4819-158-5-201303050-00004.
41. Shafer WM, Balthazar JT, Hagman KE, Morse SA. 1995. Missense mutations that alter the DNA-binding domain of the MtrR protein occur frequently in rectal isolates of Neisseria gonorrhoeae that are resistant to faecal lipids. Microbiology 141:907-911. http://dx.doi.org/10.1099/13500872 -141-4-907.